http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 21 May 2026 06:39:31 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Beam+Therapeutics+Inc+%28BEAM%29/26531121.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).</p><p>The analyst commented: "On May 18, 2026, Beam's Chief Medical Officer Amy Simon, M.D., delivered an oral presentation of additional BEAM-302 Phase 1/2 data in alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference in Orlando. Separately, on May 15, at the American Society of Gene and Cell Therapy (ASGCT) in Boston, Chief Scientific Officer Gopi Shankar, Ph.D., presented an update on BEAM-103, an anti-CD117 monoclonal antibody that enables non-genotoxic conditioning for its next-generation Engineered Stem Cell Antibody http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Beam+Therapeutics+Inc+%28BEAM%29/26531121.html Thu, 21 May 2026 06:39:31 -0400 BEAM http://www.streetinsider.com/Corporate+News/Beam+Therapeutics+presents+BEAM-302+data+at+conference/26513521.html <p>Beam Therapeutics Inc. (NASDAQ: BEAM) presented clinical data from its BEAM-302 Phase 1/2 trial for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference in Orlando, Florida.</p><p>The presentation included topline data from 29 patients treated with BEAM-302 as of February 10, 2026. The data encompassed safety results, efficacy durability and reduction in human neutrophil elastase activity following BEAM-302 treatment.</p><p>BEAM-302 is designed to correct the PiZ mutation in patients with alpha-1 antitrypsin deficiency through base editing technology. The treatment targets the liver using lipid-nanoparticle formulation to make an A-to-G correction of the mutation.</p><p>Based on feedback from the U.S. Food and http://www.streetinsider.com/Corporate+News/Beam+Therapeutics+presents+BEAM-302+data+at+conference/26513521.html Mon, 18 May 2026 16:00:29 -0400 BEAM http://www.streetinsider.com/FDA/Beam+Therapeutics+presents+BEAM-302+data+at+conference/26513521.html <p>Beam Therapeutics Inc. (NASDAQ: BEAM) presented clinical data from its BEAM-302 Phase 1/2 trial for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference in Orlando, Florida.</p><p>The presentation included topline data from 29 patients treated with BEAM-302 as of February 10, 2026. The data encompassed safety results, efficacy durability and reduction in human neutrophil elastase activity following BEAM-302 treatment.</p><p>BEAM-302 is designed to correct the PiZ mutation in patients with alpha-1 antitrypsin deficiency through base editing technology. The treatment targets the liver using lipid-nanoparticle formulation to make an A-to-G correction of the mutation.</p><p>Based on feedback from the U.S. Food and http://www.streetinsider.com/FDA/Beam+Therapeutics+presents+BEAM-302+data+at+conference/26513521.html Mon, 18 May 2026 16:00:29 -0400 BEAM http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html <p>CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.</p> <p>“At Beam, we are committed to leading innovation http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+Presents+Recently+Reported+Topline+Clinical+Data+for+BEAM-302+in+Alpha-1+Antitrypsin+Deficiency+%28AATD%29+at+the+American+Thoracic+Society+%28ATS%29+2026+International+Conference/26513513.html Mon, 18 May 2026 16:00:00 -0400 A.06822034 A.31293549 BEAM O.00573636 O.20026344 O.46871614 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Beam+Therapeutics+Inc+%28BEAM%29/26489529.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).</p><p>The analyst commented: "BEAM-302 pivotal readiness and risto-cel BLA preparation remain central to our Buy thesis; we would use any weakness to accumulate shares ahead of a catalyst-rich next 12 months. On May 7, Beam reported 1Q26 results and reiterated key clinical and regulatory milestones across its liver-targeted genetic disease and hematology franchises. Most importantly, BEAM-302 continues to advance toward pivotal development in alpha-1 antitrypsin deficiency (AATD), following updated Phase 1/2 data showing rapid and durable increases in total and functional AAT, http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Beam+Therapeutics+Inc+%28BEAM%29/26489529.html Thu, 14 May 2026 06:48:05 -0400 BEAM http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html <div class="xn-content"> <p><b>The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.</b></p><p><span class="legendSpanClass"><location value="LU/us.nc.durham" idsrc="xmltag.org" >DURHAM, N.C.</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the <span>Alpha-1 Foundation</span> (A1F), today announced <span value="NASDAQ-NMS:BEAM" idsrc="xmltag.org" >Beam Therapeutics</span> as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html Wed, 13 May 2026 11:49:00 -0400 BEAM O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html <div class="xn-content"> <p><b>The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.</b></p><p><span class="legendSpanClass"><location value="LU/us.nc.durham" idsrc="xmltag.org" >DURHAM, N.C.</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the <span>Alpha-1 Foundation</span> (A1F), today announced <span value="NASDAQ-NMS:BEAM" idsrc="xmltag.org" >Beam Therapeutics</span> as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html Wed, 13 May 2026 11:49:00 -0400 BEAM O.46871614 http://www.streetinsider.com/PRNewswire/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html <div class="xn-content"> <p><b>The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.</b></p><p><span class="legendSpanClass"><location value="LU/us.nc.durham" idsrc="xmltag.org" >DURHAM, N.C.</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the <span>Alpha-1 Foundation</span> (A1F), today announced <span value="NASDAQ-NMS:BEAM" idsrc="xmltag.org" >Beam Therapeutics</span> as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html Wed, 13 May 2026 11:49:00 -0400 BEAM O.46871614 http://www.streetinsider.com/PRNewswire/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html <div class="xn-content"> <p><b>The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.</b></p><p><span class="legendSpanClass"><location value="LU/us.nc.durham" idsrc="xmltag.org" >DURHAM, N.C.</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the <span>Alpha-1 Foundation</span> (A1F), today announced <span value="NASDAQ-NMS:BEAM" idsrc="xmltag.org" >Beam Therapeutics</span> as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Beam+Therapeutics+Supports+AlphaDetect+to+Accelerate+Detection+of+Alpha-1/26484206.html Wed, 13 May 2026 11:49:00 -0400 BEAM O.46871614 http://www.streetinsider.com/Analyst+PT+Change/Beam+Therapeutics+Inc+%28BEAM%29+PT+Lowered+to+%2439+at+Bernstein+SocGen+Group/26481614.html Bernstein SocGen Group analyst William Pickering lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $39.00 (from $40.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Beam+Therapeutics+Inc+%28BEAM%29+PT+Lowered+to+%2439+at+Bernstein+SocGen+Group/26481614.html Wed, 13 May 2026 07:15:21 -0400 BEAM http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html <p style="padding-left:0pt;">CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=SxoMaaPbix9WRCHxLbvQQEzsU0WCWdozDWdcQYWf0bthf_5M9tnQaYkwbQF_xyrke8i8iQYfey4bn8JaM9HPwvYv47oRi9KAT4Os1DCGK4k=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.</p> <p>The live webcast will be available in the investor section of the company&apos;s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kvZI7gQAFhYif5dR2P9BjPCh0KJAg2IS1gMBQohjg2iQldKyIrKgJLim6tHyT-m9IrubtvZ5P0oCkL0xZRdRDg==" rel="nofollow" target="_blank">www.beamtx.com</a> and will be archived for 60 days following the presentation.</p> <p><strong>About Beam Therapeutics</strong><br/>Beam Therapeutics (Nasdaq: BEAM) http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html Wed, 13 May 2026 07:00:00 -0400 BEAM O.46871614 http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html <p style="padding-left:0pt;">CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=SxoMaaPbix9WRCHxLbvQQEzsU0WCWdozDWdcQYWf0bthf_5M9tnQaYkwbQF_xyrke8i8iQYfey4bn8JaM9HPwvYv47oRi9KAT4Os1DCGK4k=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.</p> <p>The live webcast will be available in the investor section of the company&apos;s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kvZI7gQAFhYif5dR2P9BjPCh0KJAg2IS1gMBQohjg2iQldKyIrKgJLim6tHyT-m9IrubtvZ5P0oCkL0xZRdRDg==" rel="nofollow" target="_blank">www.beamtx.com</a> and will be archived for 60 days following the presentation.</p> <p><strong>About Beam Therapeutics</strong><br/>Beam Therapeutics (Nasdaq: BEAM) http://www.streetinsider.com/Press+Releases/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html Wed, 13 May 2026 07:00:00 -0400 BEAM O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html <p style="padding-left:0pt;">CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=SxoMaaPbix9WRCHxLbvQQEzsU0WCWdozDWdcQYWf0bthf_5M9tnQaYkwbQF_xyrke8i8iQYfey4bn8JaM9HPwvYv47oRi9KAT4Os1DCGK4k=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.</p> <p>The live webcast will be available in the investor section of the company&apos;s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kvZI7gQAFhYif5dR2P9BjPCh0KJAg2IS1gMBQohjg2iQldKyIrKgJLim6tHyT-m9IrubtvZ5P0oCkL0xZRdRDg==" rel="nofollow" target="_blank">www.beamtx.com</a> and will be archived for 60 days following the presentation.</p> <p><strong>About Beam Therapeutics</strong><br/>Beam Therapeutics (Nasdaq: BEAM) http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html Wed, 13 May 2026 07:00:00 -0400 BEAM O.46871614 http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html <p style="padding-left:0pt;">CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=SxoMaaPbix9WRCHxLbvQQEzsU0WCWdozDWdcQYWf0bthf_5M9tnQaYkwbQF_xyrke8i8iQYfey4bn8JaM9HPwvYv47oRi9KAT4Os1DCGK4k=" rel="nofollow" target="_blank">Beam Therapeutics Inc.</a> (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.</p> <p>The live webcast will be available in the investor section of the company&apos;s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kvZI7gQAFhYif5dR2P9BjPCh0KJAg2IS1gMBQohjg2iQldKyIrKgJLim6tHyT-m9IrubtvZ5P0oCkL0xZRdRDg==" rel="nofollow" target="_blank">www.beamtx.com</a> and will be archived for 60 days following the presentation.</p> <p><strong>About Beam Therapeutics</strong><br/>Beam Therapeutics (Nasdaq: BEAM) http://www.streetinsider.com/Globe+Newswire/Beam+Therapeutics+to+Present+at+2026+RBC+Capital+Markets+Global+Healthcare+Conference/26481411.html Wed, 13 May 2026 07:00:00 -0400 BEAM O.46871614